Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and ...

STOCKHOLM, December 16, 2025 /PRNewswire/ --Affibody AB ("Affibody") today announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand ...

Denali Therapeutics (DNLI) announced the publication of results from the open-label Phase 1/2 clinical trial of its investigational, ...

Silo Pharma, Inc. (Nasdaq: SILO) ("Silo” or the "Company”), a diversified developmental stage biopharmaceutical and ...

Lexaria Bioscience ( ($LEXX) ) has issued an update. Lexaria released additional secondary and exploratory results from its 12‑week Phase 1b ...

KELOWNA, BC / / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a ...

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...

KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the follo ...

Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...

Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...

A recent study by the Khazanah Research Institute (KRI) has found that while public transport in Greater Kuala Lumpur is ...